NCT ID | Title | Compound | Phase | Status | Sponsor | Participants | Last Updated |
|---|---|---|---|---|---|---|---|
| NCT06564818 | A Study of Psilocybin in Major Depressive Disorder | PSILOCYBIN | Phase 2 | Recruiting | Cybin IRL Limited | 220 | Feb 2026 |
| NCT07251491 | Psilocybin to Treat Depression in Spinal Cord Injury | PSILOCYBIN | Phase 1, Phase 2 | Not Yet Recruiting | James J. Peters Veterans Affairs Medical Center | 30 | Jan 2026 |
| NCT06795659 | Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder) | KETAMINE | Phase 1, Phase 2 | Completed | The University of Texas Health Science Center at San Antonio | 4 | Jan 2026 |
| NCT06480201 | Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression | KETAMINE | Phase 1 | Recruiting | Baylor College of Medicine | 100 | Jan 2026 |
| NCT06731621 | Psilocybin for Treatment-Resistant Depression | PSILOCYBIN | Phase 2 | Not Yet Recruiting | Johns Hopkins University | 100 | Jan 2026 |
| NCT06888128 | State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma | PSILOCYBIN | Phase 2 | Recruiting | Baylor College of Medicine | 15 | Jan 2026 |
| NCT07227909 | NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy | PSILOCYBIN | Phase 2 | Not Yet Recruiting | M.D. Anderson Cancer Center | 83 | Jan 2026 |
| NCT04578938 | Ketamine + Cognitive Training for Suicidality in the Medical Setting | KETAMINE | Phase 4 | Active Not Recruiting | Rebecca Price | 200 | Jan 2026 |
| NCT05711940 | Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD | PSILOCYBIN | Phase 3 | Active Not Recruiting | COMPASS Pathways | 572 | Jan 2026 |
| NCT06656702 | Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis | PSILOCYBIN | Early Phase 1 | Recruiting | Johns Hopkins University | 24 | Jan 2026 |
| NCT06885996 | Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence | PSILOCYBIN | Phase 2 | Not Yet Recruiting | University of Calgary | 76 | Jan 2026 |
| NCT04060108 | Stanford Regulating Circuits of the Brain Study - MDMA | MDMA | N/A | Completed | Stanford University | 22 | Jan 2026 |
| NCT07309471 | Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD | LSD | NA | Not Yet Recruiting | University Hospital, Basel, Switzerland | 24 | Dec 2025 |
| NCT05220410 | The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation | PSILOCYBIN | Phase 2 | Completed | Sheppard Pratt Health System | 20 | Dec 2025 |
| NCT07301632 | Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial | MDMA | Phase 2 | Not Yet Recruiting | Unity Health Toronto | 40 | Dec 2025 |
| NCT07102576 | MDMA-Assisted Therapy for Mental Healthcare Providers | MDMA | Phase 1 | Recruiting | Rachel Yehuda | 30 | Dec 2025 |
| NCT06070649 | The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD) | DMT | Phase 1 | Recruiting | Yale University | 63 | Dec 2025 |
| NCT05399498 | Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder | PSILOCYBIN | Phase 2 | Completed | University of Chicago | 9 | Dec 2025 |
| NCT05624268 | Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD | PSILOCYBIN | Phase 3 | Active Not Recruiting | COMPASS Pathways | 255 | Dec 2025 |
| NCT05854667 | Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users | MDMA | Phase 2 | Recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 440 | Dec 2025 |
| NCT06941844 | A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge) | LSD | Phase 3 | Recruiting | Definium Therapeutics | 140 | Dec 2025 |
| NCT06308653 | Psilocybin for Major Depressive Disorder (MDD) | PSILOCYBIN | Phase 3 | Active Not Recruiting | Usona Institute | 240 | Dec 2025 |
| NCT07281352 | RCT of Psilocybin-assisted CBT for Depression | PSILOCYBIN | Phase 1, Phase 2 | Recruiting | University of California, Los Angeles | 50 | Dec 2025 |
| NCT05450432 | Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | KETAMINE | Phase 4 | Recruiting | Massachusetts General Hospital | 100 | Dec 2025 |
| NCT07275970 | Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD | PSILOCYBIN | Phase 1 | Not Yet Recruiting | Sue Sisley | 24 | Dec 2025 |
| NCT05979844 | MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD | MDMA | Phase 3 | Completed | Dr. Leslie Morland | 16 | Dec 2025 |
| NCT07053917 | Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability | PSILOCYBIN | Phase 1 | Not Yet Recruiting | Johns Hopkins University | 20 | Nov 2025 |
| NCT05455996 | MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers | MDMA | Phase 2 | Not Yet Recruiting | Nautilus Sanctuary | 30 | Nov 2025 |
| NCT06081179 | Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans | MDMA | Phase 1 | Completed | University of Zurich | 122 | Nov 2025 |
| NCT07183748 | Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression | PSILOCYBIN | Phase 2 | Recruiting | Beersheva Mental Health Center | 20 | Nov 2025 |
| NCT06081179 | Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans | PSILOCYBIN | Phase 1 | Completed | University of Zurich | 122 | Nov 2025 |
| NCT05546658 | Effects of Psilocybin in Obsessive Compulsive Disorder | PSILOCYBIN | Early Phase 1 | Recruiting | Johns Hopkins University | 30 | Nov 2025 |
| NCT07226232 | Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression | PSILOCYBIN | Phase 3 | Not Yet Recruiting | VA Office of Research and Development | 240 | Nov 2025 |
| NCT06407635 | A Study of Psilocybin for PTSD | PSILOCYBIN | Phase 1 | Active Not Recruiting | Johns Hopkins University | 20 | Oct 2025 |
| NCT04620759 | Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder | PSILOCYBIN | Phase 2 | Active Not Recruiting | Johns Hopkins University | 90 | Oct 2025 |
| NCT06786325 | Wellcome Leap Psilocybin for OUD | PSILOCYBIN | Phase 2 | Recruiting | Anna Rose Childress, Ph.D. | 36 | Oct 2025 |
| NCT06367738 | Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults | PSILOCYBIN | Phase 1 | Recruiting | University of California, Berkeley | 40 | Oct 2025 |
| NCT04161066 | Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine | PSILOCYBIN | Phase 1 | Recruiting | University of Wisconsin, Madison | 10 | Oct 2025 |
| NCT07169747 | Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa | PSILOCYBIN | Phase 2 | Not Yet Recruiting | Region Skane | 40 | Sep 2025 |
| NCT06233344 | Mindfulness-assisted Psychedelic Therapy | PSILOCYBIN | Phase 2 | Recruiting | University of Southern California | 40 | Sep 2025 |
| NCT06788444 | Efficacy of Esketamine for Patients With Irritable Bowel Syndrome | KETAMINE | NA | Recruiting | Beijing Tiantan Hospital | 552 | Sep 2025 |
| NCT06832683 | Efficacy of Propofol-Ketamine and Sevoflurane in Children Undergoing Magnetic Resonance Imaging | KETAMINE | NA | Completed | Kocaeli City Hospital | 230 | Sep 2025 |
| NCT04950608 | Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care | PSILOCYBIN | Phase 2 | Active Not Recruiting | Yvan Beaussant, MD, MSci | 15 | Sep 2025 |
| NCT06608277 | Ketamine, SGB and Combination Treatment for TBI | KETAMINE | Phase 2 | Recruiting | Northwestern University | 175 | Aug 2025 |
| NCT06810765 | Trifecta Research Study | DMT | Phase 2 | Withdrawn | Johns Hopkins University | 0 | Aug 2025 |
| NCT05305105 | Effects of Psilocybin in Post-Treatment Lyme Disease | PSILOCYBIN | Phase 1 | Completed | Johns Hopkins University | 20 | Aug 2025 |
| NCT05733546 | A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder | PSILOCYBIN | Phase 2 | Active Not Recruiting | COMPASS Pathways | 102 | Aug 2025 |
| NCT07104916 | Mindfulness-based Psilocybin Therapy for PTSD | PSILOCYBIN | Phase 2 | Not Yet Recruiting | Anthony P King | 30 | Aug 2025 |
| NCT07079852 | The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function | PSILOCYBIN | Phase 1, Phase 2 | Not Yet Recruiting | Manoj Doss | 48 | Jul 2025 |
| NCT04264026 | MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD | MDMA | Phase 2 | Completed | VA Loma Linda Health Care System | 5 | Jul 2025 |
| NCT06117306 | MDMA-assisted Massed Prolonged Exposure for PTSD | MDMA | Phase 3 | Recruiting | Healing Breakthrough | 20 | Jul 2025 |
| NCT04784143 | Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD | MDMA | Phase 2 | Terminated | Lykos Therapeutics | 26 | Jul 2025 |
| NCT07061886 | Drug Effects on Mood and Behavior - Expectancy | LSD | Early Phase 1 | Recruiting | University of Chicago | 48 | Jul 2025 |
| NCT06430541 | Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence | PSILOCYBIN | Phase 1 | Recruiting | University of Colorado, Denver | 20 | Jul 2025 |
| NCT07017478 | Mood Effects of Serotonin Agonists: Depression | LSD | Early Phase 1 | Recruiting | University of Chicago | 48 | Jul 2025 |
| NCT06418178 | Dose Optimization of MDMA-Assisted Therapy for PTSD | MDMA | Phase 2 | Recruiting | Bronx VA Medical Center | 60 | Jun 2025 |
| NCT05312151 | The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | PSILOCYBIN | Phase 2 | Completed | COMPASS Pathways | 22 | Jun 2025 |
| NCT03485287 | Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada) | MDMA | Phase 2 | Completed | Lykos Therapeutics | 4 | Jun 2025 |
| NCT01689740 | Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD | MDMA | Phase 2 | Completed | Lykos Therapeutics | 10 | Jun 2025 |
| NCT04714359 | A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD | MDMA | Phase 3 | Completed | Lykos Therapeutics | 87 | Jun 2025 |
| NCT00090064 | MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder | MDMA | Phase 2 | Completed | Lykos Therapeutics | 23 | Jun 2025 |
| NCT04077437 | A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2) | MDMA | Phase 3 | Completed | Lykos Therapeutics | 121 | Jun 2025 |
| NCT03537014 | A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1) | MDMA | Phase 3 | Completed | Lykos Therapeutics | 100 | Jun 2025 |
| NCT01958593 | Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD | MDMA | Phase 2 | Terminated | Lykos Therapeutics | 6 | Jun 2025 |
| NCT02427568 | MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness | MDMA | Phase 2 | Completed | Lykos Therapeutics | 18 | Jun 2025 |
| NCT01793610 | Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD | MDMA | Phase 2 | Completed | Lykos Therapeutics | 29 | Jun 2025 |
| NCT01211405 | Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder | MDMA | Phase 2 | Completed | Lykos Therapeutics | 26 | Jun 2025 |
| NCT02008396 | Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults | MDMA | Phase 2 | Completed | Lykos Therapeutics | 12 | Jun 2025 |
| NCT03282123 | Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD | MDMA | Phase 2 | Completed | Lykos Therapeutics | 38 | Jun 2025 |
| NCT00402298 | Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - Israel | MDMA | Phase 2 | Terminated | Lykos Therapeutics | 5 | Jun 2025 |
| NCT03282123 | Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD | MDMA | Phase 2 | Completed | Lykos Therapeutics | 38 | Jun 2025 |
| NCT06372197 | Low-Income Group Psilocybin Assisted Therapy for Depression | PSILOCYBIN | NA | Completed | Matthew Hicks | 20 | Jun 2025 |
| NCT02876172 | MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD | MDMA | Phase 1, Phase 2 | Completed | Lykos Therapeutics | 12 | Jun 2025 |
| NCT05800860 | A Trial of GH001 in Patients With Treatment-resistant Depression | DMT | Phase 2 | Completed | GH Research Ireland Limited | 81 | May 2025 |
| NCT06512194 | Investigation to Understand and Optimize Psilocybin | PSILOCYBIN | Phase 2 | Recruiting | Charles Raison | 141 | May 2025 |
| NCT06884514 | Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects | PSILOCYBIN | Phase 1 | Recruiting | University Hospital, Basel, Switzerland | 24 | May 2025 |
| NCT05592379 | Consciousness, Psilocybin, and Well-Being | PSILOCYBIN | Phase 1 | Completed | University of Wisconsin, Madison | 6 | May 2025 |
| NCT06557239 | Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy | LSD | NA | Completed | Tatiana Aboulafia Brakha | 10 | May 2025 |
| NCT06247839 | The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder | PSILOCYBIN | Phase 3 | Recruiting | Sharmin Ghaznavi | 20 | May 2025 |
| NCT06247839 | The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder | PSILOCYBIN | Phase 3 | Recruiting | Sharmin Ghaznavi | 20 | May 2025 |
| NCT06940323 | Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA) | DMT | NA | Recruiting | University of California, San Francisco | 250 | May 2025 |
| NCT06812221 | Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI | DMT | Phase 1, Phase 2 | Completed | Biomind Labs Inc. | 20 | Apr 2025 |
| NCT05581797 | Psilocybin-assisted Interpersonal Therapy for Depression | PSILOCYBIN | NA | Completed | University of Otago | 5 | Apr 2025 |
| NCT06760533 | Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS) | PSILOCYBIN | Early Phase 1 | Not Yet Recruiting | NYU Langone Health | 10 | Apr 2025 |
| NCT06252506 | Molecular Imaging Study of Harmine/DMT: a Basic Research Approach | DMT | Phase 1 | Completed | Insel Gruppe AG, University Hospital Bern | 17 | Mar 2025 |
| NCT05219175 | MDMA for Co-occurring PTSD and OUD After Childbirth | MDMA | Phase 2 | Recruiting | University of New Mexico | 15 | Mar 2025 |
| NCT03181763 | Evaluation of MDMA on Startle Response | MDMA | Phase 1 | Completed | Lykos Therapeutics | 34 | Mar 2025 |
| NCT06789705 | Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls | MDMA | NA | Recruiting | University Hospital, Basel, Switzerland | 24 | Feb 2025 |
| NCT05804708 | Phase 2 Clinical Trial of GH001 in Postpartum Depression | DMT | Phase 2 | Terminated | GH Research Ireland Limited | 10 | Feb 2025 |
| NCT06450210 | Safety for Home Administration of Microdose Psilocybin Use | PSILOCYBIN | Phase 1 | Recruiting | Johns Hopkins University | 20 | Feb 2025 |
| NCT04030169 | Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study | MDMA | Phase 2 | Completed | MAPS Europe B.V. | 21 | Jan 2025 |
| NCT04670081 | Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression | PSILOCYBIN | Phase 2 | Completed | Central Institute of Mental Health, Mannheim | 144 | Jan 2025 |
| NCT05481736 | Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study | PSILOCYBIN | Phase 2 | Completed | COMPASS Pathways | 32 | Dec 2024 |
| NCT05979727 | Dose-finding PKPD Trial for RE02 in Healthy Subjects | DMT | Phase 1 | Terminated | Reconnect Labs | 4 | Nov 2024 |
| NCT05557643 | PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout | PSILOCYBIN | Phase 1 | Completed | University of Utah | 24 | Nov 2024 |
| NCT04438512 | A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD | MDMA | N/A | No Longer Available | Lykos Therapeutics | 0 | Nov 2024 |
| NCT02102802 | Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD | MDMA | N/A | Completed | Lykos Therapeutics | 10 | Nov 2024 |
| NCT02954562 | Correlates of Anxiety Associated With a Life-threatening Illness | MDMA | N/A | Completed | Lykos Therapeutics | 12 | Nov 2024 |
| NCT04968938 | Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD | MDMA | Phase 2 | Withdrawn | Lykos Therapeutics | 0 | Nov 2024 |
| NCT04454684 | A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders | MDMA | Phase 2 | Withdrawn | Lykos Therapeutics | 0 | Oct 2024 |
| NCT01404754 | Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers | MDMA | Phase 1 | Completed | Lykos Therapeutics | 107 | Oct 2024 |
| NCT04073433 | Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2) | MDMA | Phase 1 | Withdrawn | Lykos Therapeutics | 0 | Oct 2024 |
| NCT05147402 | Food Effects on Bioavailability of MDMA in Healthy Volunteers | MDMA | Phase 1 | Completed | Lykos Therapeutics | 14 | Oct 2024 |
| NCT03606538 | MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function | MDMA | Phase 1 | Not Yet Recruiting | Lykos Therapeutics | 16 | Oct 2024 |
| NCT05066282 | Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD | MDMA | N/A | Completed | Lykos Therapeutics | 186 | Oct 2024 |
| NCT05173831 | Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans | MDMA | Phase 2 | Withdrawn | Lykos Therapeutics | 0 | Oct 2024 |
| NCT05948683 | Prosocial Effects of MDMA | MDMA | Early Phase 1 | Completed | University of Chicago | 33 | Aug 2024 |
| NCT05646303 | Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD) | PSILOCYBIN | Phase 2 | Unknown | Clairvoyant Therapeutics | 128 | Aug 2024 |
| NCT04433858 | An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD) | PSILOCYBIN | Phase 2 | Active Not Recruiting | Sheppard Pratt Health System | 27 | Aug 2024 |
| NCT06522711 | Virtual Reality for Anxiolysis and Pharmacological Sparing | KETAMINE | NA | Not Yet Recruiting | Ciusss de L'Est de l'Île de Montréal | 100 | Jul 2024 |
| NCT00353938 | Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder | MDMA | Phase 2 | Completed | Lykos Therapeutics | 14 | Jul 2024 |
| NCT05553691 | SPL026 With or Without SSRIs in Participants With MDD | DMT | Phase 1 | Completed | Small Pharma Ltd | 18 | Jun 2024 |
| NCT06444243 | Psilocybin-assisted Therapy for Alcohol Use Disorder | PSILOCYBIN | Phase 2 | Not Yet Recruiting | University of Sydney | 90 | Jun 2024 |
| NCT04646694 | The Ketamine for Acute Postoperative Analgesia (KAPA) Trial | KETAMINE | Phase 3 | Completed | University Health Network, Toronto | 40 | May 2024 |
| NCT05644093 | IM and IV SPL026 Drug Product in Healthy Participants | DMT | Phase 1 | Completed | Small Pharma Ltd | 14 | Mar 2024 |
| NCT04522804 | Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer | PSILOCYBIN | Early Phase 1 | Completed | University of Utah | 12 | Mar 2024 |
| NCT03345173 | Facilitating Rapid Naltrexone Initiation | KETAMINE | Phase 3 | Active Not Recruiting | New York State Psychiatric Institute | 100 | Feb 2024 |
| NCT01458327 | Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial | MDMA | Phase 2 | Completed | Lykos Therapeutics | 3 | Jan 2024 |
| NCT05381974 | The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD | PSILOCYBIN | Phase 2 | Withdrawn | Massachusetts General Hospital | 0 | Jan 2024 |
| NCT05379959 | Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function | MDMA | Early Phase 1 | Completed | University of Chicago | 43 | Jan 2024 |
| NCT05548075 | Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action | PSILOCYBIN | NA | Unknown | Imperial College London | 20 | Jan 2024 |
| NCT05548075 | Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action | PSILOCYBIN | NA | Unknown | Imperial College London | 20 | Jan 2024 |
| NCT06189027 | Epigenetics and MDMA-Assisted Psychotherapy for PTSD | MDMA | Phase 3 | Unknown | University of Southern California | 45 | Jan 2024 |
| NCT05698095 | Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers | DMT | Phase 1 | Completed | Usona Institute | 54 | Nov 2023 |
| NCT04739865 | The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression | PSILOCYBIN | Phase 2 | Completed | COMPASS Pathways | 19 | Nov 2023 |
| NCT03341689 | Psilocybin for the Treatment of Migraine Headache | PSILOCYBIN | Phase 1 | Completed | Yale University | 14 | Oct 2023 |
| NCT04476446 | An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives | KETAMINE | Phase 3 | Completed | Janssen-Cilag, S.A. | 41 | Sep 2023 |
| NCT05864417 | A Study to Assess Effect of Two Facial Sunscreens in Improving Wrinkles, Fine Lines and Melasma in Adult Participants | LSD | NA | Completed | Johnson & Johnson Consumer Inc. (J&JCI) | 40 | Aug 2023 |
| NCT05478278 | An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics | PSILOCYBIN | Phase 1 | Completed | Usona Institute | 60 | Aug 2023 |
| NCT04698603 | Clinical Study of GH001 in Depression | DMT | Phase 1, Phase 2 | Completed | GH Research Ireland Limited | 16 | Aug 2023 |
| NCT03506880 | Project MADD - NIH Underage DUI and Ride | MDMA | NA | Completed | Penn State University | 2,352 | Jun 2023 |
| NCT05895318 | Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD | MDMA | NA | Completed | Albany Research Institute, Inc. | 30 | Jun 2023 |
| NCT03866174 | A Study of Psilocybin for Major Depressive Disorder (MDD) | PSILOCYBIN | Phase 2 | Completed | Usona Institute | 104 | Jun 2023 |
| NCT05467761 | Bioavailability Study of Psilocybin in Normal Adults | PSILOCYBIN | Phase 1 | Withdrawn | University of Wisconsin, Madison | 0 | May 2023 |
| NCT03775200 | The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression | PSILOCYBIN | Phase 2 | Completed | COMPASS Pathways | 233 | Apr 2023 |
| NCT04129086 | Ketamine for Acute Pain Management After Trauma | KETAMINE | Phase 4 | Completed | The University of Texas Health Science Center, Houston | 305 | Apr 2023 |
| NCT04656301 | Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder | PSILOCYBIN | Phase 2 | Completed | New York State Psychiatric Institute | 12 | Mar 2023 |
| NCT05732155 | Preliminary Effectiveness of Individual and Group MDMA-assisted Therapy for Israeli Veterans With PTSD and Moral Injury. | MDMA | Phase 2 | Unknown | HaEmek Medical Center, Israel | 60 | Feb 2023 |
| NCT04798950 | Bronchi Dilation in Polynesian Patients: Monocentric Retrospective Study | LSD | NA | Unknown | Centre Hospitalier Intercommunal Creteil | 500 | Feb 2023 |
| NCT04353921 | PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder | PSILOCYBIN | N/A | Terminated | Usona Institute | 24 | Dec 2022 |
| NCT04433845 | The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. | PSILOCYBIN | Phase 2 | Unknown | Sheppard Pratt Health System | 15 | Oct 2022 |
| NCT03933865 | Acute Pain Management in Patients on Opioid Replacement Therapy | KETAMINE | Phase 1 | Terminated | University of California, San Francisco | 1 | Oct 2022 |
| NCT04519957 | Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU) | PSILOCYBIN | N/A | Completed | COMPASS Pathways | 66 | Sep 2022 |
| NCT04661514 | Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy | PSILOCYBIN | Phase 2 | Completed | University of California, San Diego | 16 | Jul 2022 |
| NCT05180149 | Personality and Drug Use (PDU) | LSD | NA | Withdrawn | Quantified Citizen Technologies Inc. | 0 | Apr 2022 |
| NCT05180149 | Personality and Drug Use (PDU) | PSILOCYBIN | NA | Withdrawn | Quantified Citizen Technologies Inc. | 0 | Apr 2022 |
| NCT03713346 | Comparing the Digestion of Milk With Different Beta-casein Protein Content by Dairy Intolerant Persons | LSD | NA | Completed | Purdue University | 42 | Oct 2021 |
| NCT04959253 | Psilocybin in Depression Resistant to Standard Treatments | PSILOCYBIN | Phase 2 | Unknown | King's College London | 60 | Jul 2021 |
| NCT04863586 | COVID-19 and Multiple Sclerosis Disease Modifying Therapies | DMT | NA | Unknown | Nottingham University Hospitals NHS Trust | 14,240 | Apr 2021 |
| NCT03965871 | Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression | KETAMINE | Phase 2 | Completed | Celon Pharma SA | 88 | Mar 2021 |
| NCT04803448 | Patient Doctor Lies | MDMA | NA | Completed | University of Utah | 619 | Mar 2021 |
| NCT02950467 | Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors | PSILOCYBIN | Phase 1 | Completed | Joshua Woolley | 30 | Jan 2021 |
| NCT01551329 | Ketamine for Depression and Alcohol Dependence | KETAMINE | Phase 1 | Completed | Yale University | 5 | Mar 2020 |
| NCT02661061 | Ketamine for Relapse Prevention in Recurrent Depressive Disorder | KETAMINE | Phase 1 | Terminated | St Patrick's Hospital, Ireland | 9 | Jan 2020 |
| NCT01148342 | Neurobiology and Pharmacokinets of Acute MDMA Administration | MDMA | Phase 1 | Completed | National Institute on Drug Abuse (NIDA) | 187 | Dec 2019 |
| NCT03231683 | Use of S+Ketamine During Target-Controlled Intravenous Anaesthesia After Abdominal Hysterectomy | KETAMINE | Phase 2 | Completed | KK Women's and Children's Hospital | 90 | Jul 2017 |
| NCT01260649 | N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression | KETAMINE | Phase 4 | Terminated | Massachusetts General Hospital | 17 | May 2017 |